Malignant melanoma with in-transit metastases refractory to programmed cell death-1 inhibitor successfully treated with local interferon-β injections: A case report.
in-transit metastasis
interferon-β
local injection
malignant melanoma
quality of life
Journal
Molecular and clinical oncology
ISSN: 2049-9469
Titre abrégé: Mol Clin Oncol
Pays: England
ID NLM: 101613422
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
received:
11
03
2021
accepted:
23
06
2021
entrez:
31
8
2021
pubmed:
1
9
2021
medline:
1
9
2021
Statut:
ppublish
Résumé
In-transit metastases (ITMs) in patients with malignant melanoma (MM) are associated with poor prognosis and a worse disease burden compared with MM without ITMs. A substantial population of patients with ITMs show no or only poor responses to newly developed therapies, such as immune checkpoint inhibitors or molecular-targeted agents. It is difficult to control the exudate and bleeding from ITMs when these medications are ineffective. In Japan, local injection of interferon-β (IFN-β) has been licensed for years as adjuvant therapy for MM. However, the evidence for IFN-β effectiveness for ITMs remains low. The present report describes a case of MM with multiple ITMs that did not respond to a programmed cell death-1 inhibitor and local injections of IFN-β at 3 million IU/day for 5 days/4 weeks but remitted upon increasing the amount of IFN-β injections to 10 consecutive days/4 weeks. Local IFN-β therapy could be an option for improving the quality of life of patients.
Identifiants
pubmed: 34462667
doi: 10.3892/mco.2021.2374
pii: MCO-0-0-02374
pmc: PMC8375038
doi:
Types de publication
Case Reports
Langues
eng
Pagination
212Informations de copyright
Copyright: © Takahara et al.
Déclaration de conflit d'intérêts
The authors declare that they have no competing interests.
Références
Br J Surg. 2004 Jun;91(6):673-82
pubmed: 15164434
J Clin Oncol. 2005 Jul 20;23(21):4588-90
pubmed: 16034040
Oncotarget. 2017 Apr 13;8(41):71181-71187
pubmed: 29050354
J Clin Oncol. 2012 Nov 1;30(31):3810-8
pubmed: 23008300
N Engl J Med. 2017 Nov 9;377(19):1824-1835
pubmed: 28891423
Arch Dermatol Res. 2008 Jul;300(6):297-301
pubmed: 18324409
J Immunother Cancer. 2020 May;8(1):
pubmed: 32376722
N Engl J Med. 2016 Nov 10;375(19):1845-1855
pubmed: 27717298
N Engl J Med. 2017 Nov 9;377(19):1813-1823
pubmed: 28891408
Case Rep Dermatol. 2014 Mar 07;6(1):74-9
pubmed: 24707255
Cytokine Growth Factor Rev. 2015 Apr;26(2):203-12
pubmed: 25511547